Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment | PLRZ Stock NewsStockTitan·Aug 20 at 12:30 AMPLRZ-1.81%
U.S. stock market midday update: Polyrizon plummets 24.07% on increased volume, with no positive support leading to capital flightPrice Alert·Jul 28 at 10:08 AMPLRZ-1.81%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jul 14 at 07:05 AMBJDX-3.02%PLRZ-1.81%
Polyrizon adopts new executive, director pay policy with bonus, equity capsPUBT·Jul 13 at 03:01 PMPLRZ-1.81%
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial | PLRZ Stock NewsStockTitan·Jul 1 at 10:32 PMPLRZ-1.81%
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial | PLRZ Stock NewsStockTitan·Jun 28 at 11:44 PMPLRZ-1.81%
Polyrizon wins central IRB clearance to start first NASARIX allergy blocker human trialPUBT·Jun 29 at 07:44 AMPLRZ-1.81%
